NRX Pharmaceuticals, Inc. Financing Cash Flow
NRX Pharmaceuticals, Inc. (NRXP) reported Financing Cash Flow of $32.96 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-14
- NRX Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $29.53M, a 2024.60% increase year-over-year.
- NRX Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $3.42M, a 54.86% decline year-over-year.
- NRX Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $4.58M, a 141.42% increase year-over-year.
- NRX Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $9.73M, a 373.52% increase year-over-year.
- NRX Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $23.28M, a 210.97% increase from fiscal 2024.
- NRX Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $7.49M, a 20.71% increase from fiscal 2023.
- NRX Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $6.20M, a 80.75% decline from fiscal 2022.
- NRX Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $32.21M, a 49.23% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 3 month as first filed | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 6 month as first filed | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 9 month as first filed | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $29.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $32.96M 10-Q · filed 2026-08-14 | $37.53M derived: sum of 3 quarters · filed 2026-08-14 | $47.26M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2026-03-31 | $3.42M 10-Q · filed 2026-05-15 | $8.00M derived: sum of 2 quarters · filed 2026-05-15 | $17.73M derived: sum of 3 quarters · filed 2026-05-15 | $19.11M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-12-31 | $4.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $14.30M derived: sum of 2 quarters · filed 2026-03-23 | $15.69M derived: sum of 3 quarters · filed 2026-08-14 | $23.28M 10-K · filed 2026-03-23 | ||||
| 2025-09-30 | $9.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $11.12M derived: sum of 2 quarters · filed 2026-08-14 | $18.70M 10-Q · filed 2025-11-14 | $20.60M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-06-30 | $1.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $8.97M 10-Q · filed 2026-08-14 | $10.87M derived: sum of 3 quarters · filed 2026-08-14 | $12.92M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-03-31 | $7.58M 10-Q · filed 2026-05-15 | $9.48M derived: sum of 2 quarters · filed 2026-05-15 | $11.53M derived: sum of 3 quarters · filed 2026-05-15 | $14.68M derived: sum of 4 quarters · filed 2026-05-15 | ||||
| 2024-12-31 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $3.95M derived: sum of 2 quarters · filed 2026-03-23 | $7.09M derived: sum of 3 quarters · filed 2026-03-23 | $7.49M 10-K · filed 2026-03-23 | ||||
| 2024-09-30 | $2.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $5.20M derived: sum of 2 quarters · filed 2025-11-14 | $5.59M 10-Q · filed 2025-11-14 | $4.47M derived: sum of 4 quarters · filed 2025-11-14 | ||||
| 2024-06-30 | $3.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-18 | $3.54M 10-Q · filed 2025-08-18 | $2.42M derived: sum of 3 quarters · filed 2025-08-18 | $919.00K derived: sum of 4 quarters · filed 2025-08-18 | ||||
| 2024-03-31 | $395.00K 10-Q · filed 2025-05-15 | -$721.00K derived: sum of 2 quarters · filed 2025-05-15 | -$2.22M derived: sum of 3 quarters · filed 2025-05-15 | $4.05M derived: sum of 4 quarters · filed 2025-05-15 | ||||
| 2023-12-31 | -$1.12M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | -$2.62M derived: sum of 2 quarters · filed 2025-03-14 | $3.66M derived: sum of 3 quarters · filed 2025-03-14 | $6.20M 10-K · filed 2025-03-14 | ||||
| 2023-09-30 | -$1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $4.77M derived: sum of 2 quarters · filed 2024-11-14 | $7.32M 10-Q · filed 2024-11-14 | $17.44M derived: sum of 4 quarters · filed 2024-11-14 | ||||
| 2023-06-30 | $6.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $8.82M 10-Q · filed 2024-08-14 | $18.94M derived: sum of 3 quarters · filed 2024-08-14 | $18.91M derived: sum of 4 quarters · filed 2024-08-14 | ||||
| 2023-03-31 | $2.54M 10-Q · filed 2024-05-14 | $12.67M derived: sum of 2 quarters · filed 2024-05-14 | $12.64M derived: sum of 3 quarters · filed 2024-05-14 | $11.78M derived: sum of 4 quarters · filed 2024-05-14 | ||||
| 2022-12-31 | $10.12M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $10.09M derived: sum of 2 quarters · filed 2024-03-29 | $9.23M derived: sum of 3 quarters · filed 2024-03-29 | $32.21M 10-K · filed 2024-03-29 | ||||
| 2022-09-30 | -$28.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$888.00K derived: sum of 2 quarters · filed 2023-11-14 | $22.09M 10-Q · filed 2023-11-14 | $22.09M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | -$860.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $22.12M 10-Q · filed 2023-08-14 | $22.12M derived: sum of 3 quarters · filed 2023-08-14 | $59.64M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | $22.98M 10-Q · filed 2023-05-15 | $22.98M derived: sum of 2 quarters · filed 2023-05-15 | $60.50M derived: sum of 3 quarters · filed 2023-05-15 | $72.01M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $37.52M derived: sum of 2 quarters · filed 2023-03-31 | $49.03M derived: sum of 3 quarters · filed 2023-03-31 | $63.46M 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | $37.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $49.03M derived: sum of 2 quarters · filed 2022-11-14 | $63.45M 10-Q · filed 2022-11-14 | $63.45M 10-Q · filed 2021-11-15 | $64.44M derived: sum of 4 quarters · filed 2022-11-14 | |||
| 2021-06-30 | $11.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $25.94M 10-Q · filed 2022-08-15 | $25.94M 10-Q · filed 2021-08-16 | $26.92M derived: sum of 3 quarters · filed 2022-08-15 | $28.34M derived: sum of 4 quarters · filed 2022-08-15 | |||
| 2021-03-31 | $14.43M 10-Q · filed 2022-05-16 | $178.66K 10-Q · filed 2021-05-21 | $15.41M derived: sum of 2 quarters · filed 2022-05-16 | $16.83M derived: sum of 3 quarters · filed 2022-08-12 | $43.45M derived: sum of 4 quarters · filed 2022-08-12 | |||
| 2020-12-31 | $980.37K derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-03-31 | $2.40M derived: sum of 2 quarters · filed 2022-08-12 | $29.02M derived: sum of 3 quarters · filed 2022-08-12 | $3.25M 10-K · filed 2022-03-31 | -$25.58M 10-K · filed 2021-04-01 | |||
| 2020-09-30 | $1.42M derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2022-08-12 | $28.04M derived: sum of 2 quarters · filed 2022-08-12 | $2.27M 10-Q/A · filed 2022-08-12 | -$25.80M 10-Q · filed 2020-11-16 | -$7.31M derived: sum of 4 quarters · filed 2022-08-12 | |||
| 2020-06-30 | $26.62M derived: 10-Q/A 6 month − 10-Q 3 month · filed 2022-08-12 | $846.84K 10-Q/A · filed 2022-08-12 | -$25.60M 10-Q · filed 2020-08-14 | -$8.73M derived: sum of 3 quarters · filed 2022-08-12 | -$17.42M derived: sum of 4 quarters · filed 2022-08-12 | |||
| 2020-03-31 | -$25.77M 10-Q · filed 2021-05-21 | -$35.35M derived: sum of 2 quarters · filed 2021-05-21 | -$44.03M derived: sum of 3 quarters · filed 2021-05-21 | -$66.03M derived: sum of 4 quarters · filed 2021-05-21 | ||||
| 2019-12-31 | -$9.58M derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-05-14 | -$18.26M derived: sum of 2 quarters · filed 2021-05-14 | -$40.26M derived: sum of 3 quarters · filed 2021-05-14 | -$39.46M 10-K/A · filed 2021-05-14 | ||||
| 2019-09-30 | -$8.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | -$30.69M derived: sum of 2 quarters · filed 2020-11-16 | -$29.89M 10-Q · filed 2020-11-16 | -$29.20M derived: sum of 4 quarters · filed 2020-11-16 | ||||
| 2019-06-30 | -$22.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | -$21.20M 10-Q · filed 2020-08-14 | -$20.51M derived: sum of 3 quarters · filed 2020-08-14 | -$20.51M derived: sum of 4 quarters · filed 2020-08-14 | ||||
| 2019-03-31 | $796.64K 10-Q · filed 2020-05-15 | $1.49M derived: sum of 2 quarters · filed 2020-05-15 | $1.49M derived: sum of 3 quarters · filed 2020-05-15 | $1.49M derived: sum of 4 quarters · filed 2020-05-15 | ||||
| 2018-12-31 | $690.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | $690.00K derived: sum of 2 quarters · filed 2020-03-30 | $690.00K derived: sum of 3 quarters · filed 2020-03-30 | $682.50K 10-K · filed 2020-03-30 | ||||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $0.00 derived: sum of 2 quarters · filed 2019-11-14 | -$7.50K 10-Q · filed 2019-11-14 | $82.50K 10-Q · filed 2018-11-08 | ||||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | -$7.50K 10-Q · filed 2019-08-14 | $69.58M derived: sum of 3 quarters · filed 2019-08-14 | |||||
| 2018-03-31 | -$7.50K 10-Q · filed 2019-05-15 | $69.58M derived: sum of 2 quarters · filed 2019-05-15 | ||||||
| 2017-12-31 | $69.59M 10-K · filed 2019-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |